Comprehensive Analysis Reveals PTK6 as a Prognostic Biomarker Involved in the Immunosuppressive Microenvironment in Breast Cancer

Table 1

The association between PTK6 expression and characteristics of patients suffering from BC.

Characteristic	Low expression of PTK6	High expression of PTK6
	541	542
Age, (%)			0.035
≤60	318 (29.4%)	283 (26.1%)
>60	223 (20.6%)	259 (23.9%)
T stage, (%)			0.051
T1	133 (12.3%)	144 (13.3%)
T2	326 (30.2%)	303 (28.1%)
T3	71 (6.6%)	68 (6.3%)
T4	10 (0.9%)	25 (2.3%)
N stage, (%)			0.015
N0	283 (26.6%)	231 (21.7%)
N1	172 (16.2%)	186 (17.5%)
N2	48 (4.5%)	68 (6.4%)
N3	33 (3.1%)	43 (4%)
M stage, (%)			0.254
M0	455 (49.3%)	447 (48.5%)
M1	7 (0.8%)	13 (1.4%)
Pathologic stage, (%)			0.043
Stage I	93 (8.8%)	88 (8.3%)
Stage II	326 (30.8%)	293 (27.6%)
Stage III	105 (9.9%)	137 (12.9%)
Stage IV	6 (0.6%)	12 (1.1%)
Histological type, (%)			0.152
Infiltrating ductal carcinoma	376 (38.5%)	396 (40.5%)
Infiltrating lobular carcinoma	112 (11.5%)	93 (9.5%)
Age, median (IQR)	56 (47, 66)	59 (50, 69)	0.001